Laryngeal squamous cell carcinoma · line 1 · Cisplatin concurrent with definitive RT (larynx-preservation CRT; RTOG 91-11)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	local_therapy
Linked regimen	`REG-CISPLATIN-CONCURRENT-RT-LARYNX`

ID	`IND-LARYNGEAL-LA-1L-CRT`
Type	Indication
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	`DIS-LARYNGEAL`
Sources	`SRC-NCCN-HNSCC-2025` `SRC-RTOG-9111-FORASTIERE-2003`

Notes

STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Locally advanced larynx-preservation pathway — default_indication of ALGO-LARYNGEAL-1L overall. Alternative track: IND-LARYNGEAL-LA-1L-TOTAL-LARYNGECTOMY. §17 phased indication; recommended_regimen preserved for backward-compat render paths per the RC-CROSS-NEOADJ precedent. Full Ukrainian rationale/do_not_do prose deferred to a follow-up localization pass.

Used By

Algorithms

ALGO-LARYNGEAL-1L - ALGO-LARYNGEAL-1L

Indication

IND-LARYNGEAL-LA-1L-TOTAL-LARYNGECTOMY - IND-LARYNGEAL-LA-1L-TOTAL-LARYNGECTOMY